Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).

被引：1
|
作者：
Gaballa, S.
Al-Kali, A.
Kantarjian, H.
Jabbour, E.
Quintas-Cardama, A.
Ayoubi, M.
Borthakur, G.
O'Brien, S. M.
Cortes, J. E.
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6597
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML)
    Gurguis, Christopher
    de Armas, Lizette Rodriguez
    Kantarjian, Hagop M.
    Boddu, Prajwal C.
    Jain, Preetesh
    Borthakur, Gautam
    Giza, Dana Elena
    Iliescu, Gloria
    Lopez-Mattei, Juan
    Kim, Peter
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Wierda, William G.
    Kornblau, Steven
    Jabbour, Elias J.
    Iliescu, Cezar
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [2] Pulmonary Hypertension in Cancer Patients Treated with Tyrosine Kinase Inhibitors
    Patnaik, Soumya
    de Armas, Lissette R.
    Giza, Dana E.
    Balanescu, Dinu V.
    Donisan, Teodora
    Lopez-Mattei, Juan
    Kim, Peter
    Iliescu, Gloria
    Thompson, Kara
    Mouhayar, Elie
    Daver, Naval
    Durand, Jean-Bernard
    Cortes, Jorge E.
    Iliescu, Cezar
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S149 - S150
  • [3] Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Sam, Princy Yohannan
    Ahaneku, Hycienth
    Nogueras-Gonzalez, Graciela M.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Daver, Naval
    Kadia, Tapan
    Burger, Jan
    Pierce, Sherry
    DiNardo, Courtney D.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [4] Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).
    McGarry, Lisa J.
    Burudpakdee, Chakkarin
    Gala, Smeet
    Seetasith, Arpamas
    Nanavaty, Merena
    Huang, Hui
    BLOOD, 2014, 124 (21)
  • [5] No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
    Iglesias, Lilian
    Mukherjee, Sudipto
    Nazha, Aziz
    Advani, Anjali S.
    Gerds, Aaron T.
    Carraway, Hetty E.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Majhail, Navneet S.
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
  • [6] Outcomes of patients with advanced CML treated with allogeneic hematopoietic stem cell transplantation in the Era of tyrosine kinase inhibitors (TKIs)
    Kongtim, P.
    Adekola, K.
    Milton, D.
    Ramlal, R.
    Jimenez, A.
    Chen, J.
    Rondon, G.
    Ahmed, S.
    Betul, O.
    Popat, U.
    Cortes, J.
    Champlin, R.
    Ciurea, S.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S425 - S425
  • [7] Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Abruzzese, Elisabetta
    Scortechini, Anna Rita
    Gugliotta, Gabriele
    Pierri, Ivana
    Musolino, Caterina
    Iurlo, Alessandra
    Mastrullo, Lucia
    Caracciolo, Clementina
    Orlandi, Ester
    Galimberti, Sara
    Salvucci, Marzia
    Avanzini, Paolo
    Sica, Simona
    Alimena, Giuliana
    Bocchia, Monica
    Pregno, Patrizia
    D'Emilio, Anna
    Gambacorti-Passerini, Carlo
    Stagno, Fabio
    Santorsola, Domenico
    Castagnetti, Fausto
    Perrotti, Alessio Pio
    de Fabritiis, Paolo
    Baccarani, Michele
    BLOOD, 2014, 124 (21)
  • [8] Predictive role of biological markers in nsclc patients (pts) treated with EGFR tyrosine kinase inhibitors (TKIS): A metanalysis of randomized trials
    Garassino, Marina C.
    Di Cosimo, Serena
    Borgonovo, Karen
    La Verde, Nicla
    Bareggi, Claudia
    Cinquini, Michela
    Farina, Gabriella
    Torri, Valter
    ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
  • [9] Prognostic significance of prior best response to imatinib in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP)Treated with second generation tyrosine kinase inhibitors (TKIs)
    Jabbour, Elias
    Kantarjian, Hagop
    Shan, Jenny
    O'Brien, Susan
    Wierda, William
    Ravandi, Farhad
    Borthakur, Gautant
    Komblau, Steven
    Walker, Brenda K.
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 577A - 577A
  • [10] Predictive role of biological markers in NSCLC patients (pts) treated with EGFR tyrosine kinase inhibitors (TKIs): a metanalysis of randomized trials
    Garassino, M.
    Borgonovo, K.
    Cinquini, M.
    Martelli, O.
    Petricca, A. Mancuso
    La Verde, N.
    Sburati, R.
    Bramati, A.
    Farina, G.
    Torri, V.
    EJC SUPPLEMENTS, 2007, 5 (04): : 368 - 368
12345